Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Rises By 25.0%

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 246,900 shares, an increase of 25.0% from the October 31st total of 197,500 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average trading volume of 79,200 shares, the short-interest ratio is currently 3.1 days.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in XTNT. Evernest Financial Advisors LLC bought a new position in Xtant Medical in the third quarter valued at $27,000. Geode Capital Management LLC increased its stake in Xtant Medical by 70.2% in the third quarter. Geode Capital Management LLC now owns 515,006 shares of the medical device company’s stock valued at $348,000 after acquiring an additional 212,394 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Xtant Medical by 3.2% in the first quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock valued at $1,812,000 after acquiring an additional 48,319 shares during the last quarter. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Price Performance

Shares of NYSEAMERICAN:XTNT remained flat at $0.40 during trading on Monday. The company’s stock had a trading volume of 196,477 shares, compared to its average volume of 105,424. The stock has a market capitalization of $55.60 million, a P/E ratio of -3.08 and a beta of 0.39. Xtant Medical has a 12-month low of $0.39 and a 12-month high of $1.45. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Tuesday, November 12th. The medical device company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $27.94 million during the quarter. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum set a $1.50 target price on Xtant Medical and gave the stock a “buy” rating in a research report on Friday, October 18th.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.